Found: 14
Select item for more details and to access through your institution.
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.
- Published in:
- Oncologist, 2024, v. 29, n. 9, p. e1149, doi. 10.1093/oncolo/oyae079
- By:
- Publication type:
- Article
How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology.
- Published in:
- Current Oncology, 2024, v. 31, n. 6, p. 3513, doi. 10.3390/curroncol31060259
- By:
- Publication type:
- Article
Nonsteroidal Anti-inflammatory Drug-induced Colonic Strictures: Two Cases and Literature Review.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 1995, v. 90, n. 11, p. 2035
- By:
- Publication type:
- Article
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial.
- Published in:
- Colorectal Disease, 2021, v. 23, n. 6, p. 1357, doi. 10.1111/codi.15585
- By:
- Publication type:
- Article
Cancers colorectaux métastatiques non résécables : stratégies de désescalade.
- Published in:
- Hépato-Gastro & Oncologie Digestive, 2019, v. 26, n. 6, p. 573, doi. 10.1684/hpg.2019.1791
- By:
- Publication type:
- Article
Cancers colorectaux métastatiques non résécables : une stratégie d'escalade est-elle possible ?
- Published in:
- Hépato-Gastro & Oncologie Digestive, 2019, v. 26, n. 1, p. 59, doi. 10.1684/hpg.2018.1725
- By:
- Publication type:
- Article
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study.
- Published in:
- JNCI Cancer Spectrum, 2023, v. 7, n. 5, p. 1, doi. 10.1093/jncics/pkad064
- By:
- Publication type:
- Article
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
- Published in:
- Cancers, 2024, v. 16, n. 8, p. 1515, doi. 10.3390/cancers16081515
- By:
- Publication type:
- Article
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.
- Published in:
- Cancers, 2020, v. 12, n. 6, p. 1429, doi. 10.3390/cancers12061429
- By:
- Publication type:
- Article
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
- Published in:
- Neuroendocrinology, 2019, v. 108, n. 4, p. 343, doi. 10.1159/000498887
- By:
- Publication type:
- Article
Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
- Published in:
- Neuroendocrinology, 2017, v. 106, n. 1, p. 38, doi. 10.1159/000457955
- By:
- Publication type:
- Article
Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
- Published in:
- International Journal of Cancer, 2021, v. 148, n. 7, p. 1731, doi. 10.1002/ijc.33392
- By:
- Publication type:
- Article
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD‐NADEGE cohort study of 347 patients.
- Published in:
- International Journal of Cancer, 2020, v. 147, n. 4, p. 967, doi. 10.1002/ijc.32860
- By:
- Publication type:
- Article
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
- Published in:
- PLoS ONE, 2015, v. 10, n. 8, p. 1, doi. 10.1371/journal.pone.0135907
- By:
- Publication type:
- Article